Examinando por Autor "Chuqui Coronel, Segundo Miguel"
Mostrando 1 - 1 de 1
- Resultados por página
- Opciones de ordenación
Ítem Acceso Abierto Eficacia y seguridad de los inhibidores del cotransportador de sodio glucosa-2 versus los agonistas del receptor del péptido similar al glucagón-1, en personas con diabetes tipo 2 y enfermedad renal crónica: revisión sistemática(Universidad Católica de Cuenca., 2025) Chuqui Coronel, Segundo Miguel; Redrovan Coraizaca, Andres Leonardo; Idrovo Vázquez, Víctor Aníbal; 0302503388; 0302627807Background: Diabetes is a serious global health problem, with an estimated prevalence of 425 million in 2017, which is projected to decline to nearly 360 million by 2045, according to the International Diabetes Federation (IDF). A significant complication is chronic kidney disease, which develops in nearly half of individuals previously diagnosed with type 2 diabetes mellitus. Therefore, there is an urgent need for more effective and safer approaches. Objective: To evaluate the efficacy and safety of Sodium-glucose cotransporter type 2 (SGLT2) inhibitors compared to Glucagon-Like Peptide-1 (GLP-1) agonists in the treatment of adult patients with type 2 diabetes mellitus and chronic kidney disease. Methods: This systematic review will follow the PRISMA 2020 methodology, which will enhance the quality of this review. Additionally, various health determinants will be used to conduct a comprehensive search for information. Results: SGLT-2 inhibitors indicated a significant reduction in HbA1c levels with a value of -0.8%, representing an effect estimate of the presented variables, along with a 95% confidence interval. On the other hand, GLP-1 agonists showed a reduction of -0.7%, with 95% confidence interval, indicating no significant differences between both variables, especially in terms of safety. SGLT-2 inhibitors were associated with a higher risk of urogenital infections, while GLP-1 agonists indicated an increased incidence of nausea and vomiting. Therefore, both types of medications are effective, but present patterns of adverse events that should be considered in clinical practice. Keywords: GLP-1 agonists, diabetes mellitus, SGLT-2 inhibitors
